Editorial

Secondary Hypertension due to Drugs and Toxins—A Challenge for Research on Harm

Authors: Sonal Singh, MD, Amit Nautiyal, MD

Abstract

Hypertension is a major independent risk factor for cardiovascular disease and mortality. Despite more than five decades of the expansion of therapeutic regimens for hypertension, the treatment of hypertension still remains a therapeutic challenge. Data from the third National Health and Nutrition Survey (NHANES III) suggest that only 29 to 34% of hypertensive patients are adequately controlled.1

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Hyman DJ, Pavlik VN. Characteristics of patients with uncontrolled hypertension in the United States.N Engl J Med 2001;345:479–486.
 
2. Papadopoulos DP, Papademetriou V. Resistant hypertension: diagnosis and management. J Cardiovasc Pharmacol Ther 2006;11:113–118.
 
3. Gyamlani G, Geraci SA. Secondary hypertension due to drugs and toxins. South Med J 2007;100:665–666.
 
4. La Grenade L, Graham DJ, Nourjah P. Underreporting of hemorrhagic stroke associated with phenylpropanolamine. JAMA 2001;286:3081.
 
5. Wald NJ, Morris JK. Teleoanalysis: combining data from different types of study. BMJ 2003;327:616–618.